Reply to: "Progressive cholangiopathy in COVID-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered".

J Hepatol

Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Hepatology Service, Paris, France. Electronic address:

Published: October 2021

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8223115PMC
http://dx.doi.org/10.1016/j.jhep.2021.06.024DOI Listing

Publication Analysis

Top Keywords

reply "progressive
4
"progressive cholangiopathy
4
cholangiopathy covid-19
4
covid-19 patients
4
patients diagnoses
4
diagnoses ketamine-induced
4
ketamine-induced cholangiopathy
4
cholangiopathy considered"
4
cholangiopathy
2
reply
1

Similar Publications

We appreciate Reierson's thoughtful commentary on our 2019 paper, which described our experiences, ethical process, judgment calls, and lessons from a 2016-2017 data-sharing pilot between Crisis Text Line and academic researchers. The commentary raises important questions about the ethical conduct of health research in the digital age, particularly regarding informed consent, potential conflicts of interest, and the protection of vulnerable populations. Our article focused specifically on the noncommercial use of Crisis Text Line data for research purposes, so we restrict our reply to points relevant to such usage.

View Article and Find Full Text PDF

Reply to Comment on: "Associations Between Contrast Sensitivity, OCT Features, and Progression From Intermediate to Late AMD".

Am J Ophthalmol

January 2025

Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA; Retina Service, Department of Ophthalmology, Massachusetts Eye and Ear, Boston, MA, USA. Electronic address:

View Article and Find Full Text PDF

Reply to: Concerns on Potential Risk of Roxadustat in Promoting Tumor Progression: Double-Edged Sword of Hypoxia-Inducible Factor-1α Activation.

J Clin Oncol

January 2025

George M. Rodgers, MD, PhD, Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; and Jeffrey A. Gilreath, PharmD, Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT, Department of Pharmacy, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!